The addition of midostaurin to standard chemotherapy decreases cumulative incidence of relapse (CIR) in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603 / RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations Meeting Abstract
| Authors: | Stone, R. M.; Mandrekar, S. J.; Sanford, B. L.; Laumann, K.; Geyer, S. M.; Bloomfield, C. D.; Dohner, K.; Thiede, C.; Marcucci, G.; Lo Coco, F.; Klisovic, R. B.; Wei, A.; Sierra, J.; Sanz, M. A.; Brandwein, J. M.; de Witte, T. M. M.; Niederwieser, D.; Appelbaum, F. R.; Medeiros, B. C.; Tallman, M. S.; Krauter, J.; Schlenk, R. F.; Ganser, A.; Serve, H.; Ehninger, G.; Amadori, S.; Dohner, H.; Larson, R. A. |
| Abstract Title: | The addition of midostaurin to standard chemotherapy decreases cumulative incidence of relapse (CIR) in the international prospective randomized, placebo-controlled, double-blind trial (CALGB 10603 / RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutations |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419406213 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.2580.2580 |
| Notes: | Meeting Abstract: 2580 -- Source: Wos |
